| Company Name: |
Abydos Scientific |
| Tel: |
18936879710 18851749494 |
| Email: |
sales@abydoscientific.com |
|
| | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione Basic information |
| Product Name: | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione | | Synonyms: | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione;(7S,9S)-9-acetyl-9-amino-7-[(2-deoxy-β-D-erythropentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11dihydroxynaphthacene-5,12-dione;5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-α-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S-cis)- (9CI);(+)-(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy-beta-D-erythro-pent...;Cis-Amrubicin;(2R)-Amrubicin | | CAS: | 92395-36-3 | | MF: | C25H25NO9 | | MW: | 483.47 | | EINECS: | | | Product Categories: | | | Mol File: | 92395-36-3.mol | ![(7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione Structure](CAS/20180703/GIF/92395-36-3.gif) |
| | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione Chemical Properties |
| Boiling point | 717.8±60.0 °C(Predicted) | | density | 1.60±0.1 g/cm3(Predicted) | | pka | 7.83±0.60(Predicted) | | InChIKey | VJZITPJGSQKZMX-BRYWZICWNA-N | | SMILES | O([C@@]1([H])OC[C@@H](O)[C@@H](O)C1)[C@H]1C[C@](N)(C(=O)C)CC2=C(C3C(C4=CC=CC=C4C(=O)C=3C(O)=C12)=O)O |&1:1,5,7,10,12,r| |
| | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione Usage And Synthesis |
| Uses | (R)-Amrubicin ((R)-SM-5887) is an anthracycline that effectively treats lung cancer by intercalating into DNA and inhibiting topoisomerase II activity, which consequently hampers DNA replication as well as RNA and protein synthesis, leading to cell growth inhibition and apoptosis. This compound exhibits superior anti-tumor efficacy compared to traditional anthracycline drugs while lacking the cumulative cardiac toxicity typically associated with this drug class. |
| | (7S-cis)-9-Acetyl-9-amino-7-[(2-deoxy-alpha-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione Preparation Products And Raw materials |
|